BioWorld MedTech

Aug. 6, 2014

NewCo on the Go: A nosy new technology may offer solution for Alzheimer's disease

A nose device designed to target nerve trunks and stimulate the brain structures that control memory and cognition is catching attention as a potential new therapy for central nervous system diseases, including Alzheimer's. Read More

Philips, Accenture partnership could give ALS patients more independence

Inside the Beltway: CMS says no to new DRG for MitraClip, Abbott unenthused

World in Brief: Lombard's Aorfix will begin sales of AAA grafts in Japan

Agreements/contracts: CareView in pilot patient monitoring agreement with Shea Medical Center

Daily M&A: Varian acquires assets of Transpire, including Acuros

Grants: Oraya receives $215K small business grant from NIH for Oraya Therapy

People in Places

Hit Bits: Healthways and Gallup reach new milestone in joint venture

Product briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...